Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499234 | 0.76 | TRPV4 (0.38) | TRPV4 | |
| SCHEMBL601168 | 0.74 | TRPV4 (0.37) | TRPV4 | |
| SCHEMBL1499272 | 0.73 | TRPV4 (0.35) | TRPV4 | |
| SCHEMBL17028455 | 0.72 | KDM4E (0.33) | TRPV4 | |
| SCHEMBL19304814 | 0.70 | TRPV4 (0.33) | TRPV4 | |
| SCHEMBL8309613 | 0.67 | TRPV4 (0.34) | TRPV4HSP90AA1HSP90AB1 | |
| SCHEMBL19450884 | 0.64 | HSP90AA1 (0.36) | TRPV4HSP90AA1HSP90AB1 | |
| SCHEMBL3295796 | 0.63 | TRPV4 (0.48) | TRPV4HSP90AA1HSP90AB1 | |
| SCHEMBL25408294 | 0.62 | HSP90AA1 (0.31) | HSP90AA1HSP90AB1 | |
| SCHEMBL1149372 | 0.62 | HSP90AA1 (0.35) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | claimed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | claimed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | claimed |
| US-8299262-B2 | Pyridylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-10-30 | — | — | US | claimed |
| JP-2011506281-A | — | — | 2011-03-03 | — | — | JP | claimed |
| EP-2262794-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE AS FUNGICIDE | BASF SE (DE) | 2010-12-22 | — | — | EP | claimed |
| US-20100317516-A1 | Sulfonamide Compounds And Their Use As Fungicide | BASF SE (DE) | 2010-12-16 | — | — | US | claimed |
| US-20100249077-A1 | Pyridylmethyl-Sulfonamide Compounds | BASF SE (DE) | 2010-09-30 | — | — | US | claimed |
| EP-2231605-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2010-09-29 | — | — | EP | claimed |
| WO-2009103650-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE AS FUNGICIDE | BASF SE (DE) | 2009-08-27 | — | — | WO | claimed |
| WO-2009071448-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-06-11 | — | — | WO | claimed |
| WO-2009071449-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-06-11 | — | — | WO | claimed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-2231605-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009103650-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE AS FUNGICIDE | BASF SE (DE) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009071448-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071449-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317516-A1 | Sulfonamide Compounds And Their Use As Fungicide | STS, ARSA, CYP4X1 | TRPV4 3462/4885HSP90AA1 2075/4885HSP90AB1 1949/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | TRPV4 3419/4885HSP90AA1 2769/4885HSP90AB1 2277/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | TRPV4 3417/4885HSP90AA1 2743/4885HSP90AB1 2246/4885 |
| US-20100249077-A1 | Pyridylmethyl-Sulfonamide Compounds | CBR3, CBR1, CBS | TRPV4 1673/4885HSP90AA1 1979/4885HSP90AB1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.